Takeda has announced that
alogliptin, marketed in Australia
as Nesina, has demonstrated
strong CV safety in the EXAMINE
Cardiovascular Safety Outcomes
Trial presented at the American
College of Cardiology meeting in
Washington DC.
Alogliptin is the first and only
DPP-4i to demonstrate CV safety
outcomes in Type 2 diabetes
patients with recent acute coronary
syndrome (ACS).
Prof Henry Krumm, Monash
University, Melbourne and the
Georgia Institute, Sydney, said the
new data generally supported the
CV safety of alogliptin in high risk
patients following an ACS event.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Apr 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.